schliessen

Filtern

 

Bibliotheken

Emerging Strategies for Increasing High-Density Lipoprotein

High-density lipoprotein cholesterol is a potent and independent epidemiologic risk factor and is a proved antiatherosclerotic agent in animal models of atherosclerosis, acting through the principal mechanisms of accelerating cholesterol efflux and inhibiting oxidation and inflammation. Lifestyle mo... Full description

Journal Title: The American Journal of Cardiology 2006, Vol.98(11), pp.1542-1549
Main Author: Forrester, James S
Other Authors: Shah, Prediman K
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0002-9149 ; E-ISSN: 1879-1913 ; DOI: 10.1016/j.amjcard.2006.06.059
Link: https://www.sciencedirect.com/science/article/pii/S0002914906016481
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_amjcard_2006_06_059
title: Emerging Strategies for Increasing High-Density Lipoprotein
format: Article
creator:
  • Forrester, James S
  • Shah, Prediman K
subjects:
  • Medicine
ispartof: The American Journal of Cardiology, 2006, Vol.98(11), pp.1542-1549
description: High-density lipoprotein cholesterol is a potent and independent epidemiologic risk factor and is a proved antiatherosclerotic agent in animal models of atherosclerosis, acting through the principal mechanisms of accelerating cholesterol efflux and inhibiting oxidation and inflammation. Lifestyle modification increases serum levels by 5% to 15%, whereas niacin, the drug most widely used to increase high-density lipoprotein cholesterol, increases it by 25% to 35% at the highest doses. This review examines the potent methods of increasing high-density lipoprotein and/or enhancing reverse cholesterol transport, including cholesterol ester transfer protein inhibitors, apolipoprotein A-I Milano, D4F, the dual peroxisome proliferator–activated receptor agonists, and rimonabant, that are now in clinical trials. In conclusion, these new agents, used alone or in combination with existing therapies, carry the potential to markedly reduce the incidence of new coronary disease and cardiac...
language: eng
source:
identifier: ISSN: 0002-9149 ; E-ISSN: 1879-1913 ; DOI: 10.1016/j.amjcard.2006.06.059
fulltext: fulltext
issn:
  • 0002-9149
  • 00029149
  • 1879-1913
  • 18791913
url: Link


@attributes
ID1836042468
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_amjcard_2006_06_059
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_amjcard_2006_06_059
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAQFI
17ABBQC
18ABFNM
19ABMZM
20ABYKQ
21ACDAQ
22ACIUM
23ACRLP
24AEKER
25AEVXI
26AFKWA
27AFTJW
28AFXIZ
29AGHFR
30AGUBO
31AGYEJ
32AHHHB
33AIKHN
34AITUG
35AJBFU
36AJOXV
37AJRQY
38AJUYK
39AMFUW
40ANZVX
41BLXMC
42BNPGV
43EO9
44EP2
45EP3
46FDB
47FGOYB
48FIRID
49FNPLU
50G-Q
51GBLVA
52HEB
53HMK
54HMO
55J1W
56KOM
57LCYCR
58OA.
59OAUVE
60OL~
61P-8
62P-9
63PC.
64Q38
65R2-
66RPZ
67SAE
68SDF
69SDG
70SEL
71SES
72SSH
73SSZ
74T5K
75UV1
76Z5R
77~G-
pqid68182742
galeid161254467
display
typearticle
titleEmerging Strategies for Increasing High-Density Lipoprotein
creatorForrester, James S ; Shah, Prediman K
ispartofThe American Journal of Cardiology, 2006, Vol.98(11), pp.1542-1549
identifier
subjectMedicine
descriptionHigh-density lipoprotein cholesterol is a potent and independent epidemiologic risk factor and is a proved antiatherosclerotic agent in animal models of atherosclerosis, acting through the principal mechanisms of accelerating cholesterol efflux and inhibiting oxidation and inflammation. Lifestyle modification increases serum levels by 5% to 15%, whereas niacin, the drug most widely used to increase high-density lipoprotein cholesterol, increases it by 25% to 35% at the highest doses. This review examines the potent methods of increasing high-density lipoprotein and/or enhancing reverse cholesterol transport, including cholesterol ester transfer protein inhibitors, apolipoprotein A-I Milano, D4F, the dual peroxisome proliferator–activated receptor agonists, and rimonabant, that are now in clinical trials. In conclusion, these new agents, used alone or in combination with existing therapies, carry the potential to markedly reduce the incidence of new coronary disease and cardiac...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914906016481$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Forrester, James S
1Shah, Prediman K
titleEmerging Strategies for Increasing High-Density Lipoprotein
description

High-density lipoprotein cholesterol is a potent and independent epidemiologic risk factor and is a proved antiatherosclerotic agent in animal models of atherosclerosis, acting through the principal mechanisms of accelerating cholesterol efflux and inhibiting oxidation and inflammation. Lifestyle modification increases serum levels by 5% to 15%, whereas niacin, the drug most widely used to increase high-density lipoprotein cholesterol, increases it by 25% to 35% at the highest doses. This review examines the potent methods of increasing high-density lipoprotein and/or enhancing reverse cholesterol transport, including cholesterol ester transfer protein inhibitors, apolipoprotein A-I Milano, D4F, the dual peroxisome proliferator–activated receptor agonists, and rimonabant, that are now in clinical trials. In conclusion, these new agents, used alone or in combination with existing therapies, carry the potential to markedly reduce the incidence of new coronary disease and cardiac...

subjectMedicine
general
0English
1Elsevier Inc
210.1016/j.amjcard.2006.06.059
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_amjcard_2006_06_059
issn
00002-9149
100029149
21879-1913
318791913
rsrctypearticle
creationdate2006
addtitleThe American Journal of Cardiology
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAQFI
17ABBQC
18ABFNM
19ABMZM
20ABYKQ
21ACDAQ
22ACIUM
23ACRLP
24AEKER
25AEVXI
26AFKWA
27AFTJW
28AFXIZ
29AGHFR
30AGUBO
31AGYEJ
32AHHHB
33AIKHN
34AITUG
35AJBFU
36AJOXV
37AJRQY
38AJUYK
39AMFUW
40ANZVX
41BLXMC
42BNPGV
43EO9
44EP2
45EP3
46FDB
47FGOYB
48FIRID
49FNPLU
50G-Q
51GBLVA
52HEB
53HMK
54HMO
55J1W
56KOM
57LCYCR
58OA.
59OAUVE
60OL~
61P-8
62P-9
63PC.
64Q38
65R2-
66RPZ
67SAE
68SDF
69SDG
70SEL
71SES
72SSH
73SSZ
74T5K
75UV1
76Z5R
77~G-
startdate20060101
enddate20061231
lsr40The American Journal of Cardiology, 2006, Vol.98 (11), pp.1542-1549
doi10.1016/j.amjcard.2006.06.059
citationpf 1542 pt 1549 vol 98 issue 11
lsr30VSR-Enriched:[pqid, date, galeid]
sort
titleEmerging Strategies for Increasing High-Density Lipoprotein
authorForrester, James S ; Shah, Prediman K
creationdate20060000
lso0120060000
facets
frbrgroupid4374418696878682013
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Forrester, James S
1Shah, Prediman K
jtitleAmerican Journal of Cardiology
creationdate2006
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Forrester
1Shah
aufirst
0James S
1Prediman K
auinitJ
auinit1J
au
0Forrester, James S
1Shah, Prediman K
atitleEmerging Strategies for Increasing High-Density Lipoprotein
jtitleThe American Journal of Cardiology
risdate2006
volume98
issue11
spage1542
epage1549
pages1542-1549
issn0002-9149
eissn1879-1913
formatjournal
genrearticle
ristypeJOUR
abstract

High-density lipoprotein cholesterol is a potent and independent epidemiologic risk factor and is a proved antiatherosclerotic agent in animal models of atherosclerosis, acting through the principal mechanisms of accelerating cholesterol efflux and inhibiting oxidation and inflammation. Lifestyle modification increases serum levels by 5% to 15%, whereas niacin, the drug most widely used to increase high-density lipoprotein cholesterol, increases it by 25% to 35% at the highest doses. This review examines the potent methods of increasing high-density lipoprotein and/or enhancing reverse cholesterol transport, including cholesterol ester transfer protein inhibitors, apolipoprotein A-I Milano, D4F, the dual peroxisome proliferator–activated receptor agonists, and rimonabant, that are now in clinical trials. In conclusion, these new agents, used alone or in combination with existing therapies, carry the potential to markedly reduce the incidence of new coronary disease and cardiac...

pubElsevier Inc
doi10.1016/j.amjcard.2006.06.059
lad01The American Journal of Cardiology
date2006-12-01